Evaluation of the Efficacy and Safety of DM934 Versus Théalose on Eye Dryness

Dry Eye Clinical Trial

Official title:

Multicentric, Randomized, Comparative Clinical Study on the Evaluation of the Efficacy and Safety of DM934 Versus Théalose on the Treatment of Moderate to Severe Ocular Dryness

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06245421
• Other study ID #: 23E0548
• Status: Recruiting
• Phase: N/A
• Start date: March 7, 2024
• Est. completion date: December 2024

Study information

• Verified date: March 2024
• Source: Horus Pharma
• Contact: Laure Chauchat
• Phone: +33 (0)4 89 08 90 98
• Email: laure.chauchat[@]horus-pharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a multicentric, comparative, randomized, investigator-blinded, parallel group study to demonstrate the non-inferiority of DM934 in comparison with Théalose in terms of cornea and conjunctiva staining (Oxford score) on patients with moderate to severe ocular dryness, after 35 days of treatment

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: December 2024
• Est. primary completion date: October 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject with a moderate to severe dry eye syndrome needing artificial tears in the 3 months preceding the inclusion.
• Subject having used only artificial tears without preservative (NaCl 0.9%, Larmabak®) during 1 to 2 weeks before inclusion (up to 6 times a day) (given during wash-out period).
• Subject with a score = 18 for the OSDI (Ocular Surface Disease Index).
• Subject with at least one eye with:
• Global ocular staining (cornea and conjunctiva) =4 and =9 on the Oxford scale (0 to 15)

AND one of the following criteria:

• Schirmer test = 3 mm/5 min and = 9 mm/5 min OR
• Sum of 3 measurements of Tear film Break-Up Time (TBUT) = 30s.
• Subject, having given freely and expressly his/her informed consent.
• Subject who is able to comply with the study requirements, as defined in the present CIP, at the Investigator's appreciation.
• For applicable countries: subject being affiliated to a health social security system.
• Female subjects of childbearing potential should use a medically accepted contraceptive regimen since at least 12 weeks before the beginning of the study, during all the study and at least 1 month after the study end.

Exclusion Criteria:

• Far best corrected visual acuity < 1/10 (according to Snellen Chart)
• Subject with severe ocular dryness with one of these conditions:
• Eyelid or blinking malfunction
• Corneal disorders not related to dry eye syndrome
• Ocular metaplasia
• Filamentous keratitis
• Corneal neovascularization
• Subject with severe meibomian gland dysfunction (MGD).
• History of ocular trauma, infection or inflammation, not related to dry eye syndrome within the last 3 months prior to the inclusion.
• History of ocular allergy or ocular herpes within the last 12 months.
• Any troubles of the ocular surface not related to dry eye syndrome .
• Subjects who underwent ocular surgery, including laser surgery, in either eye within the last 6 months.
• Use of the following ocular treatments: isotretinoïd, cyclosporine, tacrolimus, sirolimus, pimecrolimus, punctual plugs during the month preceding the inclusion.
• Subjects who have received ocular therapy (either eye) with any ophthalmic medication, except tear substitutes, within 2 weeks prior to study start or expected to receive ocular therapy during the study.
• Any not stabilised systemic treatment, which can have an effect on performance or safety criteria, at the investigator appreciation.
• Pregnant or nursing woman or planning a pregnancy during the study.
• Subject deprived of freedom by administrative or legal decision.
• Subject in a social or health institution.
• Subject who is under guardianship or who is not able to express his/her consent.
• Subject being in an exclusion period for a previous study.
• Subject suspected to be non-compliant according to the Investigator's judgment.
• Subject wearing contact lenses during the study.

Related Conditions & MeSH terms

• Dry Eye
• Dry Eye Syndromes

Intervention

Device:
• DM934
1 drop in each eye, 4 to 6 times per day
• Théalose
1 drop in each eye, 4 to 6 times per day

Locations

Country	Name	City	State
France	Eurofins Dermscan	Aix-en-Provence
France	Eurofins EVIC	Bordeaux
Poland	Eurofins Dermscan Poland	Gdansk
Spain	IOBA	Valladolid
United Kingdom	Ocular Technology Group	London

Sponsors (2)

Lead Sponsor	Collaborator
Horus Pharma	Eurofins Dermscan Pharmascan

Countries where clinical trial is conducted

France,  Poland,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Lacrimal meniscus height (exploratory, optional)	Main change from baseline of lacrimal meniscus height in the worse eye and contralateral eye	35 days
Other	Lacrimal meniscus height (exploratory, optional)	Main change from baseline of lacrimal meniscus height in the worse eye and contralateral eye	84 days
Primary	Cornea and conjunctiva staining (Oxford score)	Evaluation of the non-inferiority of DM934 in comparison with Théalose, in terms of cornea and conjunctiva staining (Oxford score), on worse eye	35 days
Secondary	Cornea and conjunctiva staining (Oxford score) (performance)	Main change from baseline of cornea and conjunctiva staining (Oxford score) in the worse eye and contralateral eye	35 days
Secondary	Cornea and conjunctiva staining (Oxford score) (performance)	Main change from baseline of cornea and conjunctiva staining (Oxford score) in the worse eye and contralateral eye	84 days
Secondary	Tear-Film Break Up Time (TBUT) (performance)	Main change from baseline of Tear-Film Break Up Time (TBUT) in the worse eye and contralateral eye	35 days
Secondary	Tear-Film Break Up Time (TBUT) (performance)	Main change from baseline of Tear-Film Break Up Time (TBUT) in the worse eye and contralateral eye	84 days
Secondary	OSDI (questionnaire)(performance)	Main change from baseline of Ocular Surface Disease Index (OSDI) score	35 days
Secondary	OSDI (questionnaire)(performance)	Main change from baseline of Ocular Surface Disease Index (OSDI) score	84 days
Secondary	Van Bijsterveld score (performance)	Main change from baseline of Van Bijsterveld score (lissamine green staining) in the worse eye and contralateral eye	35 days
Secondary	Van Bijsterveld score (performance)	Main change from baseline of Van Bijsterveld score (lissamine green staining) in the worse eye and contralateral eye	84 days
Secondary	Schirmer test (performance)	Main change from baseline of Schirmer test result in the worse eye and contralateral eye	35 days
Secondary	Schirmer test (performance)	Main change from baseline of Schirmer test result in the worse eye and contralateral eye	84 days
Secondary	Dry eye symptoms (performance)	Mean change from Baseline in the global sum score of dry eye symptoms at D84 : discomfort,burning, stinging,eye dryness sensation, itching,foreign body sensation,photophobia, blurred vision.Each graded from 0 to 10	35 days
Secondary	Dry eye symptoms (performance)	Mean change from Baseline in the global sum score of dry eye symptoms at D84 : discomfort,burning, stinging,eye dryness sensation, itching,foreign body sensation,photophobia, blurred vision.Each graded from 0 to 10	84 days
Secondary	Global performance by the investigator (performance)	Global performance assessment by the investigator using a 4-point scale (Unsatisfactory, Not very satisfactory, Satisfactory, Very satisfactory)	35 days
Secondary	Global performance by the investigator (performance)	Global performance assessment by the investigator using a 4-point scale (Unsatisfactory, Not very satisfactory, Satisfactory, Very satisfactory)	84 days
Secondary	Global performance by the patient (performance)	Global performance assessment by the patient using a 4-point scale (Unsatisfactory, Not very satisfactory, Satisfactory, Very satisfactory)	35 days
Secondary	Global performance by the patient (performance)	lobal performance assessment by the patient using a 4-point scale (Unsatisfactory, Not very satisfactory, Satisfactory, Very satisfactory)	84 days
Secondary	Number of Adverse Events (safety)	Collection of ocular and systemic adverse events	84 days